Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.74 |
| ▸ | TNF | P01375 | 5/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.74 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.60 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412111 | 0.96 | ADORA2B (0.81) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL10522005 | 0.95 | ADORA2B (0.79) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL8570022 | 0.92 | ADORA2B (0.77) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL10519753 | 0.89 | ADORA2B (0.92) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Bisdionin C SCHEMBL10018600 | 0.87 | CHIT1 (0.75) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Bisdionin D SCHEMBL16120988 | 0.87 | ADORA2B (0.79) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Caffeine SCHEMBL16568874 | 0.86 | ADORA2B (0.71) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL10521493 | 0.86 | ADORA2B (0.70) | ADORA2BTNFUSP2LMNACYP1A2 | |
| SCHEMBL16120981 | 0.86 | ADORA2B (0.77) | ADORA2BTNFUSP2LMNACYP1A2 | |
| Pentoxifylline SCHEMBL3986204 | 0.85 | ADORA2B (1.00) | ADORA2BTNFUSP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0956855-B1 | Immunosuppressive effects of 8 substituted xanthine derivatives | LEUVEN K U RES & DEV (BE) | 2003-03-12 | — | — | EP | claimed |
| US-6075027-A | Treatment and prevention of hepatic disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-13 | — | — | US | claimed |
| EP-0956855-A1 | Immunosuppressive effects of 8-substituted xanthine derivatives | K.U. Leuven Research & Development (BE) | 1999-11-17 | — | — | EP | claimed |
| WO-1998014181-A1 | TREATMENT AND PREVENTION OF HEPATIC DISORDERS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-09 | — | — | WO | claimed |
| EP-0484785-B1 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST ROUSSEL PHARMA (US) | 1996-05-22 | — | — | EP | claimed |
| US-5112827-A | Purine derivatives, pentoxifylline, anticholesterol, arterial antideposit agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-12 | — | — | US | claimed |
| CN-117482063-A | Pentoxifylline sustained release tablet and preparation method thereof | 海南皇隆制药股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20220000875-A1 | TOPICAL COMPOSITIONS COMPRISING PENTOXIFYLLINE AND METHODS OF TREATMENT USING THE SAME | COTE TIM (US) | 2022-01-06 | — | — | US | disclosed |
| US-20200138822-A1 | TOPICAL COMPOSITIONS COMPRISING PENTOXIFYLLINE AND METHODS OF TREATMENT USING THE SAME | COTE TIM (US) | 2020-05-07 | — | — | US | disclosed |
| EP-2265612-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9493463-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493463-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150322068-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-11-12 | — | — | US | disclosed |
| US-5603954-A | DOSAGE, DRUG DELIVERY, TIME-RELEASE AGENTS | ALZA CORPORATION (US) | 1997-02-18 | — | — | US | disclosed |
| US-5532003-A | Pentoxifylline therapy | ALZA CORPORATION (US) | 1996-07-02 | — | — | US | disclosed |
| WO-1995019174-A1 | PENTOXIFYLLINE DOSAGE FORM | ALZA CORPORATION (US) | 1995-07-20 | — | — | WO | disclosed |
| EP-0493682-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0490181-A1 | Use of xanthines for preparation of a medicament having immunosuppressing activity | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-17 | — | — | EP | disclosed |
| EP-0484785-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-05-13 | — | — | EP | disclosed |
| US-5112827-A | Purine derivatives, pentoxifylline, anticholesterol, arterial antideposit agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322068-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | ADORA2B 60/4885TNF 583/4885USP2 4016/4885 |
| US-20200138822-A1 | TOPICAL COMPOSITIONS COMPRISING PENTOXIFYLLINE AND METHODS OF TREATMENT USING THE SAME | TYMP, PDE3A, PDE3B | ADORA2B 310/4885TNF 807/4885USP2 2923/4885 |
| US-20220000875-A1 | TOPICAL COMPOSITIONS COMPRISING PENTOXIFYLLINE AND METHODS OF TREATMENT USING THE SAME | TYMP, PDE3A, PDE3B | ADORA2B 310/4885TNF 807/4885USP2 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.